anti-CD22 mAb (Crucell)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD22 mAb (Crucell)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionCD226 antigen blockers

TargetsCD226 antigen

Therapy Area/IndicationsLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCrucell NV

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesCrucell NV

Active IndicationsN/A

Inactive IndicationsLeukemia

ATC CodeN/A